0001539252-16-000004.txt : 20161026
0001539252-16-000004.hdr.sgml : 20161026
20161026104541
ACCESSION NUMBER: 0001539252-16-000004
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20161026
DATE AS OF CHANGE: 20161026
EFFECTIVENESS DATE: 20161026
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Provista Diagnostics Inc.
CENTRAL INDEX KEY: 0001539252
IRS NUMBER: 274282214
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-273217
FILM NUMBER: 161951799
BUSINESS ADDRESS:
STREET 1: 17301 N. PERIMETER DRIVE, SUITE 100
CITY: SCOTTSDALE
STATE: AZ
ZIP: 85085
BUSINESS PHONE: 602-224-5500
MAIL ADDRESS:
STREET 1: 17301 N. PERIMETER DRIVE, SUITE 100
CITY: SCOTTSDALE
STATE: AZ
ZIP: 85085
D
1
primary_doc.xml
X0707
D
LIVE
0001539252
Provista Diagnostics Inc.
17301 N. PERIMETER DRIVE, SUITE 100
SCOTTSDALE
AZ
ARIZONA
85255
602-224-5500
DELAWARE
None
None
Corporation
true
David
Reese
17301 N. Perimeter Dr., Suite 100
Scottsdale
AZ
ARIZONA
85255
Executive Officer
Director
Uriel
E.
Kusiatin
55 Broad Street, 18th Floor
New York
NY
NEW YORK
10004
Executive Officer
Anne
Busquet
17301 N. Perimeter Dr., Suite 100
Scottsdale
AZ
ARIZONA
85255
Director
Jeffrey
Gilman
17301 N. Perimeter Dr., Suite 100
Scottsdale
AZ
ARIZONA
85255
Director
Robert
Hariri
17301 N. Perimeter Dr., Suite 100
Scottsdale
AZ
ARIZONA
85255
Director
Jack
Levine
17301 N. Perimeter Dr., Suite 100
Scottsdale
AZ
ARIZONA
85255
Director
John
Macaskill
17301 N. Perimeter Dr., Suite 100
Scottsdale
AZ
ARIZONA
85255
Director
John
Zicarelli
17301 N. Perimeter Dr., Suite 100
Scottsdale
AZ
ARIZONA
85255
Director
Yoji
Nimura
17301 N. Perimeter Dr., Suite 100
Scottsdale
AZ
ARIZONA
85255
Director
Thomas
Mendell
17301 N. Perimeter Dr., Suite 100
Scottsdale
AZ
ARIZONA
85255
Director
Biotechnology
Decline to Disclose
- 06b
false
2016-10-13
false
true
true
false
0
6000000
2564948
3435052
The Issuer is offering up to $6,000,000 in principal amount of convertible promissory notes. This Form D is also intended to cover the underlying equity securities.
false
5
0
0
0
false
Provista Diagnostics Inc.
/s/ Uriel E. Kusiatin
Uriel E. Kusiatin
Chief Financial Officer
2016-10-25